

Epysqli® (eculizumab-aagh) – First-time biosimilar launch

- On April 7, 2025, <u>Teva</u> and <u>Samsung Bioepis announced</u> the launch of <u>Epysqli (eculizumabaagh)</u>, biosimilar to AstraZeneca's Soliris (eculizumab).
 - Epysqli is available at a list price (Wholesale Acquisition Cost [WAC]) 30% below the current Soliris intravenous 300 mg/30 mL list price (\$6,523.00 per package).
- The FDA approved Epysqli in July 2024.
- Epysqli and Soliris share the following indications:
 - The treatment of patients with paroxysmal nocturnal hemoglobinuria to reduce hemolysis
 - The treatment of patients with atypical hemolytic uremic syndrome to inhibit complementmediated thrombotic microangiopathy.
- Soliris is also approved for the treatment of generalized myasthenia gravis in adult patients who
 are anti-acetylcholine receptor antibody positive and neuromyelitis optica spectrum disorder in
 adult patients who are anti-aquaporin-4 antibody positive.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.